RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: 4-7-8 Breathing Technique for Diabetic Neuropathies

This study aims to determine the effect of the 4-7-8 breathing technique, applied during Electromyography (EMG) for the diagnosis of diabetic peripheral neuropathy, on the pain and anxiety levels experienced by patients with Type 2 diabetes. EMG is a diagnostic method that can cause pain and anxiety in patients.

Official registry: https://clinicaltrials.gov/study/NCT07702175 · Nurgül Gün · enrollment listed as 100

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are 4-7-8 Breathing Technique. The registry lists allocation as randomized. This study aims to determine the effect of the 4-7-8 breathing technique, applied during Electromyography (EMG) for the diagnosis of diabetic peripheral neuropathy, on the pain and anxiety levels experienced by patients with Type 2 diabetes.

They plan to enroll about 100 people at Osmaniye. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

The Effect of 4-7-8 Breathing Technique on Pain and Anxiety During Electromyography Procedure in Individuals With Type 2 Diabetes Who Have Diabetic Neuropathy: A Randomized Controlled Study

Interventions: 4-7-8 Breathing Technique

Primary outcome (registry wording): Pain Score

Who it is for (from inclusion criteria)

Ages 18 Years to 70 Years
Individuals aged 18-70 years who:
Have been diagnosed with Type 2 DM for at least one year,
Have diabetic peripheral neuropathy and are taking medications with a DN4 score \>3,
Are cooperative and can communicate in Turkish. • Do not have orthopedic or surgical contraindications that would prevent them from undergoing testing

Who the registry excludes

Individuals with severe autonomic neuropathy findings (resting tachycardia, etc.),
Individuals with respiratory system diseases that prevent deep breathing, such as COPD and asthma,
Individuals with active infection or compromised skin integrity (dryness, cracks, open wounds, lesions, etc.) in the area where EMG will be performed,
Individuals with a mass (tumor, cystic formation, etc.) in the anatomical area where EMG will be performed,
Individuals with varicose veins (signs of venous insufficiency) in the anatomical area where EMG will be performed,
Individuals with edema in the area where EMG will be performed that may affect the quality of electrophysiological recordings,
Individuals with a dialysis catheter, central venous catheter, or implanted venous port,

Public study contact (from the registry)

Nurgül GÜN, MSc, RN

+90 553 869 46 78

nurgul.gun@hku.edu.tr

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Osmaniye Training and Research Hospital — Osmaniye, Osmaniye, Turkey (Türkiye) (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07702175 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07702175?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07702175?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary